Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation - PubMed (original) (raw)
. 1997 Jun;150(6):2019-31.
Affiliations
- PMID: 9176395
- PMCID: PMC1858311
Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation
K S Kilgore et al. Am J Pathol. 1997 Jun.
Abstract
Activation of the complement cascade and subsequent assembly of the membrane attack complex (MAC) occur in a number of pathophysiological settings. When formed on the surface of endothelial cells in sublytic concentrations, the MAC can induce a number of proinflammatory activities, including the secretion of soluble mediators (eg, interleukin (IL)-8 and monocyte chemoattractant protein (MCP)-1) and the up-regulation of cell surface adhesion molecules. Available data indicate that MAC-induced cell activation may occur through several complex signal transduction pathways, but little is known about the intranuclear mechanisms by which complement-derived products promote the up-regulation of inflammatory mediators. Using purified distal complement proteins (C5-9) to assemble functional MAC on early-passage human umbilical vein endothelial cells (HUVECs), we examined mechanisms of MCP-1 and IL-8 induction. Formation of sublytic concentrations of MAC promoted an increase in nuclear factor (NF)-kappa B DNA binding activity within 60 minutes as determined by serial electrophoretic mobility shift assay. Cytosolic to nuclear translocation of NF-kappa B was confirmed by Western immunoblot and immunocytochemical analyses. Formation of the C5b-8 complex also promoted NF-kappa B translocation but to a lesser degree than observed in HUVECs containing complete MAC. No cytosolic to nuclear translocation of the p65 NF-kappa B subunit was observed in unstimulated HUVECs or in cells incubated with the MAC components devoid of C7. Preincubation of HUVECs with pyrrolidine dithiocarbamate prevented MAC-induced increases in IL-8 and MCP-1 mRNA concentrations and protein secretion. A direct cause and effect linkage between MAC assembly and NF-kappa B activation was established through examination of the pharmacological effect of the peptide SN50 on IL-8 and MCP-1 expression. SN50 is a recently engineered 26-amino-acid peptide that contains a lipophilic cell-membrane-permeable motif and a nuclear localization sequence that specifically competes with the nuclear localization sequence of the NF-kappa B p50 subunit. This study provides direct in vitro evidence that the distal complement system (MAC) can promote proinflammatory endothelial cell activation, specifically, increases in IL-8 and MCP-1 mRNA concentrations and protein secretion, and that cytosolic to nuclear translocation of NF-kappa B is necessary for this response.
Similar articles
- The membrane attack complex of complement induces interleukin-8 and monocyte chemoattractant protein-1 secretion from human umbilical vein endothelial cells.
Kilgore KS, Flory CM, Miller BF, Evans VM, Warren JS. Kilgore KS, et al. Am J Pathol. 1996 Sep;149(3):953-61. Am J Pathol. 1996. PMID: 8780399 Free PMC article. - Loxosceles deserta spider venom induces NF-kappaB-dependent chemokine production by endothelial cells.
Desai A, Miller MJ, Gomez HF, Warren JS. Desai A, et al. J Toxicol Clin Toxicol. 1999;37(4):447-56. doi: 10.1081/clt-100102435. J Toxicol Clin Toxicol. 1999. PMID: 10465241 - Cytokine induction of monocyte chemoattractant protein-1 gene expression in human endothelial cells depends on the cooperative action of NF-kappa B and AP-1.
Martin T, Cardarelli PM, Parry GC, Felts KA, Cobb RR. Martin T, et al. Eur J Immunol. 1997 May;27(5):1091-7. doi: 10.1002/eji.1830270508. Eur J Immunol. 1997. PMID: 9174597 - Complement Membrane Attack Complex: New Roles, Mechanisms of Action, and Therapeutic Targets.
Xie CB, Jane-Wit D, Pober JS. Xie CB, et al. Am J Pathol. 2020 Jun;190(6):1138-1150. doi: 10.1016/j.ajpath.2020.02.006. Epub 2020 Mar 16. Am J Pathol. 2020. PMID: 32194049 Free PMC article. Review. - Mechanisms of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells.
Niculescu F, Rus H. Niculescu F, et al. Immunol Res. 2001;24(2):191-9. doi: 10.1385/ir:24:2:191. Immunol Res. 2001. PMID: 11594456 Review.
Cited by
- In a novel autoimmune and high-pressure glaucoma model a complex immune response is induced.
Reinehr S, Wulf J, Theile J, Schulte KK, Peters M, Fuchshofer R, Dick HB, Joachim SC. Reinehr S, et al. Front Immunol. 2024 Mar 7;15:1296178. doi: 10.3389/fimmu.2024.1296178. eCollection 2024. Front Immunol. 2024. PMID: 38515755 Free PMC article. - COVID, complement, and the brain.
Vlaicu SI, Tatomir A, Cuevas J, Rus V, Rus H. Vlaicu SI, et al. Front Immunol. 2023 Jul 18;14:1216457. doi: 10.3389/fimmu.2023.1216457. eCollection 2023. Front Immunol. 2023. PMID: 37533859 Free PMC article. Review. - Ldlr-/-.Leiden mice develop neurodegeneration, age-dependent astrogliosis and obesity-induced changes in microglia immunophenotype which are partly reversed by complement component 5 neutralizing antibody.
Seidel F, Fluiter K, Kleemann R, Worms N, van Nieuwkoop A, Caspers MPM, Grigoriadis N, Kiliaan AJ, Baas F, Michailidou I, Morrison MC. Seidel F, et al. Front Cell Neurosci. 2023 Jun 29;17:1205261. doi: 10.3389/fncel.2023.1205261. eCollection 2023. Front Cell Neurosci. 2023. PMID: 37457817 Free PMC article. - Increased plasma level of terminal complement complex in AMD patients: potential functional consequences for RPE cells.
Busch C, Rau S, Sekulic A, Perie L, Huber C, Gehrke M, Joussen AM, Zipfel PF, Wildner G, Skerka C, Strauß O. Busch C, et al. Front Immunol. 2023 Jun 8;14:1200725. doi: 10.3389/fimmu.2023.1200725. eCollection 2023. Front Immunol. 2023. PMID: 37359546 Free PMC article. - Complement, complosome, and complotype: A perspective.
Singh P, Kemper C. Singh P, et al. Eur J Immunol. 2023 Dec;53(12):e2250042. doi: 10.1002/eji.202250042. Epub 2023 May 11. Eur J Immunol. 2023. PMID: 37120820 Review.
References
- Lab Invest. 1995 Mar;72(3):254-71 - PubMed
- Biochem Biophys Res Commun. 1995 Jan 5;206(1):429-36 - PubMed
- J Biol Chem. 1995 Jun 23;270(25):14928-34 - PubMed
- FASEB J. 1995 Jul;9(10):899-909 - PubMed
- J Immunol. 1995 Aug 1;155(3):1434-41 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous